医学
恶性胸腔积液
胸膜成形术
内科学
荟萃分析
胸腔积液
中医药
随机对照试验
肿瘤科
病理
替代医学
作者
Cheng-Qiong Wang,Jingyu Xu,Hong Jiang,Xiao-Tian Zheng,Yan Zhang,Xiao-Rong Huang,Fei She,Teng-Yang Fan,Lin Zhan,Jihong Feng,Qihai Gong,Xue Xiao,Xiaofan Chen,Zheng Xiao
出处
期刊:Phytomedicine
[Elsevier]
日期:2023-07-01
卷期号:115: 154847-154847
被引量:1
标识
DOI:10.1016/j.phymed.2023.154847
摘要
Aidi injection (Aidi), a traditional Chinese medicine injection, is often practiced to control malignant pleural effusion (MPE). We performed a registered systematic review and meta-analysis (PROSPERO: CRD42022337611) to clarify the clinical role of Aidi in MPE, reveal optimal combinations of Aidi and chemical agents, their indications, therapeutic route and usage, and demonstrate their clinical effectiveness and safety. All randomized controlled trials (RCTs) about Aidi in controlling MPE were collected from Chinese and English databases (up to October 2022). We clustered them into multiple homogenous regimens, evaluated the risk-of-bias at outcome level using a RoB 2, extracted and pooled the data using meta-analysis or descriptive analysis, and finally summarized their evidence quality. All 56 studies were clustered into intrapleural administration with Aidi alone or plus chemical agents, and intravenous administration with Aidi for MPE. Intrapleural administration with Aidi alone displayed similar clinical responses on Cisplatin (DDP) alone. Only administration with Aidi plus DDP significantly improved complete response and quality of life, and displayed a low pleurodesis failure, disease progression, hematotoxicity, gastrointestinal and hepatorenal toxicity. For patients with moderate to massive effusion, Karnofsky Performance Status score ≥ 50 or anticipated survival time ≥3 months, Aidi (50 ml to 80 ml each time, one time each week and three to eight times) plus DDP (20 to 30 mg, 40 to 50 mg, or 60 to 80 mg each time) significantly improved clinical responses. Most results had moderate to low quality. Current evidences indicate that Aidi, a pleurodesis agent, plays an interesting clinical role in controlling MPE. Aidi plus DDP perfusion is a most commonly used regimen, which shows a significant improvement in clinical responses. These findings also provide an indication and possible optimal usage for rational drug use.
科研通智能强力驱动
Strongly Powered by AbleSci AI